Dr. John Cush RheumNow
3 years 11 months ago
Heavy Metal Rheumatology 🤘
https://t.co/4fkwOsH2yf https://t.co/otQP9a6h6S
Dr. John Cush RheumNow
3 years 11 months ago
USPSTF Recommends Screening for Anxiety and Depression
The U.S. Preventive Services Task Force has recommended that general practitioners actively screen and identify anxiety and depression in all adult patients under 65 yrs.
https://t.co/8qOHzV52d8 https://t.co/tOzZQDHR1M
Dr. John Cush RheumNow
3 years 11 months ago
Worldwide, IL-6 inhibitors are approved for RA, poly JIA, systemic JIA, AOSD, GCA, Takayasu arteritis, Castleman’s dz, CAR-T-cell-induced cytokine release syndrome, neuromyelitis optica spectrum disorder and severe COVID-19 https://t.co/SRPjerXnGS
Dr. John Cush RheumNow
3 years 11 months ago
Patients with incident gout have a 44% increased risk of 1st-time ACS, higher in women than in men. This risk is largely explained by the underlying comorbidities, Swedish study of 20,146 pts w/ incident gout. Risk decr in multivariate analysis (15-20%) https://t.co/KbjszXNFSQ
Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website.
Dr. John Cush RheumNow
3 years 11 months ago
Italian study of Apremilast in 356 #PsA (age 60yrs) pts Followed ~17 mos, shows retention rate @ 12, 24 & 36 mos to be 85.6%, 73.6%, & 61.8%. D/C primarily for inefficacy (18-34%), GI Sx (24%). Best persistence w/ oligoarthritis https://t.co/iIy86cUHB5
Dr. John Cush RheumNow
3 years 11 months ago
Open label, multicenter study of 70 Psoriasis pts treated w/ apremilast shows no change in aortic vascular inflammation (FDG-PET) at wks 16 & 52, but did decr. several cardiometabolic biomarkers (IL1b, ferritin) & 5-6% loss of SC fat https://t.co/iJOgZ5kHLb
Dr. John Cush RheumNow
3 years 11 months ago
Retrospective study of PFAPA < 18yrs, 336 pts, Boys=Girls, peak onset ~age 1 yrs (less w/ yrs); 90% 1st Sxs under 5 yrs & <3% after age 10 yrs, Common Sxs: pharyngitis w fever, Cx adenitis, aphthous stomatitis, atyp skin rash. Incidence 0.86/10K/Yr https://t.co/1Mrp9bMnuE
Dr. John Cush RheumNow
3 years 11 months ago
Metanalysis of 25 studies examined effects of NSAID therapy on COVID-19 outcomes and confirms NSAIDs do not increase the likelihood of SARS-CoV-2 infection and do not worsen outcomes in patients with COVID-19. https://t.co/FAJ58stmv1
Dr. John Cush RheumNow
3 years 11 months ago
Is PMR the Next Indication for Tocilizumab?
About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed.
https://t.co/LUMG4NnZzs https://t.co/zdFacyYyud
Dr. John Cush RheumNow
3 years 11 months ago
Clinical Profiles Seen with NXP-2 Antibodies
A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.
https://t.co/DTNohe66n1 https://t.co/Bu1qbi5Q1q
Dr. John Cush RheumNow
3 years 11 months ago
Yoga Fails to Benefit Knee Osteoarthritis
The Annals of Internal Medicine has published a study showing online yoga education and an unsupervised yoga program may improve physical function did not improve knee pain after 12 weeks and 24 weeks.
https://t.co/tmWu4t3vgX https://t.co/bJCYaCIcGE
Dr. John Cush RheumNow
3 years 11 months ago
IL-6i in Behcets? Lit Review finds 25 articles papers, 74 pts (31 TNFi naive, 45 TNFi prior Rx). Pts Rx w/ tocilizumab IV. TCZ given for vascular, CNS , ocular & mucocutaneous. TCZ was effective in 87% TNF naive & 80% in TNFi Experienced pts. https://t.co/jdJ9H04lnE https://t.co/yoxrKiIVW2
Dr. John Cush RheumNow
3 years 11 months ago
Are we set for the next "Twindemic"? - Continuation and evolution of COVID BA.5 to? - Flourishing Influenza in a population who has vaccine burnout? Some predicting severe flu based on Australia’s 2022 flu season, climate change, more https://t.co/qWuhWjaAFa
